A5113481452- Lung Cancer Research Studies
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Neuroendocrine Tumor Research Advances
- Cancer Treatment and Pharmacology
- Frailty in Older Adults
- Genomic variations and chromosomal abnormalities
- Glioma Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Adipokines, Inflammation, and Metabolic Diseases
- Multiple and Secondary Primary Cancers
- Hepatocellular Carcinoma Treatment and Prognosis
- Obesity, Physical Activity, Diet
- Cancer survivorship and care
- vaccines and immunoinformatics approaches
- Health Systems, Economic Evaluations, Quality of Life
- Brain Metastases and Treatment
- Brain Tumor Detection and Classification
- Patient-Provider Communication in Healthcare
- Pharmaceutical Economics and Policy
Hospital Virgen de la Salud
2000-2024
Universidade do Tocantins
2024
Complejo Hospitalario Universitario de Toledo
2011-2022
Spanish National Cancer Research Centre
2002
Hospital Universitario Fundación Jiménez Díaz
1997
8103 Background: The STIMULI clinical trial (NCT02046733) tested the combination of ipilimumab and nivolumab (IPI/NIVO) after standard chemoradiotherapy in patients with limited disease small cell lung cancer (LD-SCLC). study showed no improvement primary endpoint progression-free survival (PFS) unselected patients. Accessing tumor samples is challenging LD-SCLC chemoradiotherapy; hence, we analyzed serum whole blood RNA as biomarkers to stratify for benefit. Methods: We used a...
Abstract Objective To investigate the factors associated with hypercholesterolemia in older adults residing a small municipality northeastern Brazil. Methods This is population‐based cross‐sectional epidemiological study conducted 232 (women: 58.60%; men: 41.40%) Aiquara, Bahia, Independent variables included socioeconomic, behavioral, and health‐related factors. The outcome was self‐reported (yes or no). Poisson regression robust estimator used to calculate Prevalence Ratios (PR) their...
e17544 Background: To determine the direct economic impact attributable to drugs assigned patients (pts) enrolled in clinical trials (CT) by medical oncology department of a third level hospital terms avoided cost. Methods: Avoided cost: value that pts included CT should have received protocol and must not pay because are provided promoter or they replaced investigational drugs. Retrospective observational study (January 2004 - December 2013). Collecting data from records conducted Medical...
The benefits of systemic treatment NSCLC patients are greater control the symptoms and improvement HRQoL. study aimed to assess impact on daily living HRQoL advanced NSCLC. Observational with prospective follow-up (basal 6-8 week visit). 257 stage IIIB NSCLC, pleural/pericardial effusion or IV about initiate second-line were included by 32 hospitals in Spain. Demographic clinical data relating Lung Cancer Symptom Scale (LCSS) lung-specific Functional Assessment Therapy questionnaire (FACT-L)...
7093 Background: CDDP+NVBO as induction and concomitant regimen with RT has shown good efficacy outcomes safety profile (Krzakowski, J Thor Oncol. 2008). Five Spanish institutions have collected the data of patients LA NSCLC treated previously reported in order to confirm results clinical daily activity. Methods: Between February 2007 April 2009, 19 chemo-naïve (p) histologically confirmed stage IIIA/IIIB unresectable were treated. Treatment consisted NVBO D1,8 60 mg/m2 cycle (cy) 1 80 cy 2...
10649 Background: Standard C schedule is 14 days every 3 w (C14). However, data have shown that C7 as effective and significantly less toxic than C14. The objective to evaluate retrospectively the response rate toxicity of single agent or in combination heavily pretreated p with advanced solid tumours. Methods: tumour, age ≤ 75 years, ECOG PS <2 adequate bone marrow, renal hepatic functions were analyzed. received C7: 1250 mg/m 2 /12 h x 7 every-other week. drugs doses adjusted be used 1...